Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION – Is ablative radioiodine necessary for low-risk differentiated thyroid cancer patients
2011-000144-21Phase 2Unknown
- Sponsor
- University College London
- Start
- Jul 2011
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised trial of iodine-131 in well-differentiated thyroid cancer (WDTC) and follicular carcinoma (FTC) (2 arms), sponsored by University College London. Primary endpoint: Phase II monthly patient accrual rates. Status: unknown.
02
Drugs
iodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)follicular carcinoma (FTC)
Beyond the preview
Go deeper on 2011-000144-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000144-21.